Comparison of C-reactive proteins level in gestational hypertension and in normal pregnancy in 2nd and 3rd trimester and its correlation with maternal and foetal outcome

Authors

  • Rashmi Ranjan Rout Department of Obstetrics and Gynecology, VIMSAR, Burla, Odisha, India
  • Meenakshi Mahalik Department of Obstetrics and Gynecology, VIMSAR, Burla, Odisha, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20192464

Keywords:

C - reactive protein, Hypertensive pregnancy disorder

Abstract

Background: Hypertensive pregnancy disorder covers a spectrum of clinical conditions namely preeclampsia, eclampsia, chronic hypertension and gestational hypertension. Impaired function of vascular endothelium in preeclampsia may cause abnormal immune activation causing release of inflammatory agents like cytokines, C-reactive proteins (CRP) etc. Aim of this study is to evaluate the CRP (Q) levels in gestational hypertension and in normal pregnancy in 2nd and 3rd trimester and its correlation with maternal and foetal outcome.

Methods: Total 350 patients were involved in the study with 160 subjects in Study group meeting the eligibility criteria and 190 subjects in control group. All the cases were followed up during the rest part of their antenatal, labour and postpartum period for development of preeclampsia and eclampsia and their effect on mother and foetus.

Results: In 2nd and 3rd trimester mean CRP level in study group was 10.01 mg/L and 10.28 mg/L compare to control group 1.85 mg/L and 3.06 mg/L respectively. Difference of mean CRP level was statistically significant (P value <0.001) in both 2nd and 3rd trimester. Gestational age at delivery and birth weight, Apgar score for baby was lower in study group as compared to control group. Maternal morbidity, maternal mortality, mode of delivery by caesarean section, IUD, still birth, preterm delivery, IUGR, baby with respiratory distress syndrome was significantly higher in study group.

Conclusions: Increased serum CRP level can be used as a biomarker for identifying women at risk of preeclampsia and its complications along with adverse effect.

References

Wagner SJ, Barac S, Garovic VD. Hypertensive pregnancy disorders: current concepts. The Journal of Clinical Hypertension. 2007 Jul;9(7):560-6.

Cunningham. Gary F. Williams Obstetrics. 24th Ed. New York : McGraw-Hill.

Kameswaramma K. Estimation of C - Reactive Protein, Magnesium and Uric Acid Levels in PreEclampsia Patients in Comparison with Normal Pregnant Women. Scholars J Applied Med Sci. 2014;2(2B): 628-32.

Bharadwaj R, Mathur K, Saukhla M, Yadav A, Sharma D. The relationship between oxidative stress and High sensitive CRP in Pre-eclamsia. Int J Basic Applied Physiol.

Ertas IE, Kahyaoglu S, Yilmaz B, Ozel M, Sut N, Guven MA, et al. Association of maternal serum high sensitive C‐reactive protein level with body mass index and severity of pre‐eclampsia at third trimester. J Obs Gynaecol Res. 2010 Oct 1;36(5):970-7.

Lafayette RA, Druzin M, Sibley R, Derby G, Malik T. Nature of glomerular dysfunction in pre eclampsia. Kidney Int. 1998;54:1240-9.

Sibai BM, Ramadan MK, Usta I, Salma M, Mercer BM, Friedman SA. Maternal morbidity and mortality in 442 pregnancies with (HELLP syndrome ). Am J Obstet Gynaecol. 1993;169:1000-6.

Weinstein L. Syndrome of HELLP Syndrome: a severe consequence of hypertension in pregnancy. Am J Obstet Gynecol. 1982;142:159-67.

Isler CM, Rinehart BK, Terrone DA, Martin RW, Magann EF, Martin JN. Maternal mortality associated with HELLP syndrome. Am J Obstet Gynecol. 1999;181:924-8.

ACOG Practise Bulletin Committee. Diagnosis and management of Preeclampsia and eclampsia. Obstet Gynecol. 2002;99:159-67.

Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365(9461):785-99.

Du Clos TW. The interaction of C- reactive protein and serum amyloid P component with nuclear antigens. Mol Biol Rep. 1996;23(3-4):253-60.

Mandal KK, Singh YP, Das A, Devi NS, Singh NN. Serum Uric Acid and C-Reactive Protein in Preeclampsia. 2015;14(2):16-23.

Callaway LK, McIntyre HD, O'Callaghan M, Williams GM, Najman JM, Lawlor DA. The Association of Hypertensive Disorders of Pregnancy with Weight Gain over the Subsequent 21 Years: Findings from a Prospective Cohort Study. Am J Epidemiol. 2007;166(4):421‐8.

Kaur P, Desai DA, Taraiya A, Patel A. Association of serum uric acid and Creactive protein levels in prediction of pre-eclampsia. Int J Reprod Contracept Obstet Gynecol. 2016;5(2):495-502.

Ali Z, Bokhari FA, Zaki S, Zargham U, Tauseef A, Khakan S. Correlation of CRP Levels in Third Trimester with Fetal Birth Weight in Preeclamptic and Normotensive Pregnant Women. J Coll Physicians Surgeons Pak. 2015,25(2):111-4 .

Sharmin S, Chy S, diadrulalam, Banu N, Fahmida Rashid F, Kabir S. Association of Serum C-reactive Protein in Preeclampsia and its Effect on Fetal Birth Weight-A Case Control Study. Bangladesh J Obstet Gynaecol. 2016;31(2):75-80 .

Ghosh TK, Ghosh S, Bhattacharjee D. C - reactive protein levels in women with pregnancy induced hypertension. Bangladesh J Med Sci. 2011 July;10(3):159-62.

Adu-Bonsaffoh K, Ntumy MY, Obed SA, Seffah JD. Perinatal outcomes of hypertensive disorders in pregnancy at a tertiary hospital in Ghana. BMC pregnancy and childbirth. 2017 Dec;17(1):388.

Paternoster DM, Fantinato S, Stella A, Nanhornguè KN, Milani M, Plebani M, et al. C-reactive protein in hypertensive disorders in pregnancy. Clin Appl Thromb Hemost. 2006 Jul;12(3):330-7.

Abalos E, Cuesta C, Carroli G, Qureshi Z, Widmer M, Vogel JP, et al. WHO Multicountry Survey on Maternal and Newborn Health Research Network. Pre-eclampsia, eclampsia and adverse maternal and perinatal outcomes: a secondary analysis of the World Health Organization Multicountry Survey on Maternal and Newborn Health. BJOG. 2014 Mar;121 Suppl 1:14-24.

Downloads

Published

2019-05-28

Issue

Section

Original Research Articles